Ticker Details
Akebia Therapeutics, Inc. Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.
IPO Date:	March 24, 2018
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$251.22M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.14 | 3.89%
Avg Daily Range (30 D):	$0.04 | 3.58%
Avg Daily Range (90 D):	$0.04 | 3.40%

Institutional Daily Volume
Avg Daily Volume:	2.87M
Avg Daily Volume (30 D):	3.94M
Avg Daily Volume (90 D):	4.21M

Trade Size
Avg Trade Size (Sh.):	310
Avg Trade Size (Sh.) (30 D):	256
Avg Trade Size (Sh.) (90 D):	249

Institutional Trades
Total Institutional Trades:	1,040
Avg Institutional Trade:	$1.64M
Avg Institutional Trade (30 D):	$1.1M
Avg Institutional Trade (90 D):	$3.48M
Avg Institutional Trade Volume:	.5M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.57M
Avg Closing Trade (30 D):	$1.1M
Avg Closing Trade (90 D):	$3.44M
Avg Closing Volume:	497.21K

News

Jun 23, 2026 @ 5:00 PM Acute Kidney Injury Clinical Trial Pipeline Appear... Source: Delveinsight

Feb 19, 2026 @ 1:00 PM Akebia Therapeutics to Report Fourth Quarter and F... Source: Na

Feb 4, 2026 @ 1:00 PM Akebia Therapeutics to Present at the Guggenheim E... Source: Not Specified

Dec 1, 2025 @ 2:43 PM Why Is Small-Cap Q32 Bio Stock Soaring On Monday? Source: Vandana Singh

Nov 6, 2025 @ 11:30 PM Vafseo® (vadadustat) Dialysis Dependent Patient... Source: Akebia Therapeutics

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.12	$-.03	$-.03
Diluted EPS	$-.12	$-.03	$-.03
Revenue	$219.06M	$49.13M	$53.54M
Gross Profit	$174.43M	$38.7M	$41.25M
Net Income / Loss	$-29.67M	$-8.91M	$-9.05M
Operating Income / Loss	$-15.13M	$-6.33M	$-4.7M
Cost of Revenue	$44.63M	$10.42M	$12.29M
Net Cash Flow	$18.26M	$-7.09M	$-22.2M
PE Ratio